KH-3 treatment upregulated several metastatic suppressors (e.g., CD82 and CDH1)34 and downregulated several genes frequently overexpressed in breast cancer lung metastasis (such as CDH2)35. This evidence concerns the gene CDH2 and breast carcinoma.